Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 3, 2010

View Archived Issues

Suven Life Sciences presents new agents with encouraging in vivo procognitive activity

Auspex Pharmaceuticals claims deuterated SGLT-2 inhibitors

Abbott discloses new HCV serine protease NS3 inhibitors

Merck & Co. launches Dulera in U.S. for asthma

Results reported on Basilea's Toctino in severe chronic hand eczema

PAION advances phase IIb trial of anesthetic/sedative remimazolam

BrainStorm and Hadassah to begin phase I/II trial of NurOwn technology platform candidate in ALS

ACT submits response to FDA regarding phase I/II MA-09-HRPE trial in eye disease

Prolactin receptor expression is potential biomarker for colorectal cancer progression

Methylation state of HOXD3 gene identified as biomarker for prostate cancer

Promising preliminary phase II data disclosed on HIV immunotherapeutic AGS-004

Conatus Pharmaceuticals acquires Idun Pharmaceuticals from Pfizer

FDA confirms orphan drug exclusivity of Wilate for von Willebrand's disease

Astellas and Kotobuki disclose new SGLT-1 and SGLT-2 inhibitors

German scientists identify new HIF-1-alpha inhibitors

Dainippon Sumitomo Pharma presents new Na(V)1.8 channel inhibitors

Cardioxyl reports phase I/IIa data on CXL-1020 in heart failure

Servier to develop and commercialize Osteologix's NBS-101 outside U.S.

Repligen receives funds to develop HDAC inhibitors in Friedreich's ataxia and HD

FDA approves Xeomin for cervical dystonia and blepharospasm

Quest Diagnostics' XSense test for fragile X syndrome approved in New York state

ArQule and Daiichi Sankyo advance ARQ-197 to phase III in non-small cell lung cancer

BioMarin reports topline phase II data on PEG-PAL in PKU

BioMarin discontinues development of BMN-195

Reduced TSPO expression and low progesterone are linked to MDD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...